Italy In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…
Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…
Spain mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing facility, and its partnership with AstraZeneca on COVID-19 vaccine manufacturing in Argentina. As representatives from the US FDA carried out a Good Clinical Practice inspection in an adjacent office, Lepine outlined…
Saudi Arabia Emcure’s Senior VP for the Middle East, North & West Africa, Afghanistan, Pakistan & Turkey, Amr El-Neklawy, highlights the level of organizational independence given to his region, the necessity of agility and focus when competing in the generics market, and how the Indian multinational is standing out by offering its…
Global In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status of the biosimilars industry, the differences between the European and US markets, the advantages of being part of a large science-based innovator like Novartis, and why competition in biosimilars will…
Spain The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain – including the nearly EUR one billion in savings they bring to the system – the most important elements included in the upcoming national plan to promote the…
Italy Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and analyses the potential impact of recent changes to Italy’s pricing and reimbursement system. The pandemic showed us the importance…
Turkey With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological pharmaceuticals has reached 30 percent globally, a rate that is expected to continue increasing, but the market share in Turkey…
Turkey Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges of executing an integration of two companies during the COVID-19 pandemic. Güner outlines Viatris’ role within Turkey’s Vision 2023, the opportunities for their biosimilars pipeline, and their portfolio’s role in…
Turkey Arven Pharmaceuticals is the Turkish R&D-based company behind the first biosimilar drug developed and manufactured from cell to final product in the country, and the first patented and produced dry powder inhaler in Turkey. Its founder and president, Zafer Toksöz, explains the company’s pioneering journey and the circumstances that have…
Denmark Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not only to provide medicines but also contribute to the overall ecosystem. von Würden also explains the logic and relevance of the company’s M&A activity in Denmark in recent years, highlights…
Turkey Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon Kang and commercial director, Mahmut Uyar, outline the Korean company’s strong performance in 2020, how they are leveraging their commercial…
See our Cookie Privacy Policy Here